15 November 2024 – Medtronic plc, a global leader in healthcare technology, has announced CE Mark approval for its next generation Endoflip™ 300 system.
This advanced diagnostic tool measures pressure and dimensions in the oesophagus and pylorus, aiding in the diagnosis of oesophageal motility disorders, which are often missed during endoscopies.
Dr. Rehan Haidry, Clinical Lead of Endoscopy and Consultant Gastroenterologist at the Cleveland Clinic, London, highlights the significance of this innovation: “Endoflip is a game changer for us. Oesophageal motility disorders, like achalasia and gastroparesis, are notorious for being hard to spot and patients are often given the wrong diagnosis. I’ve seen patients with symptoms for over a decade, undergoing numerous inconclusive endoscopies. Endoflip provides us with a significant advantage: by guiding diagnosis and treatment early on, Endoflip™ can drastically improve patient outcomes.”
The Endoflip™ 300 system can be performed under sedation in around 5 minutes and can be utilised from the very first endoscopy, offering a more precise diagnosis and treatment planning. This timely diagnosis is key to improving patient outcomes and preventing unnecessary distress.
Dr Rehan Haidry is highly experienced in using Endoflip and the procedure is available at the Cleveland Clinic. Click here to find out more.